Sarah Ketterer's AZN Position Overview
Sarah Ketterer (via Causeway Capital Management LLC) currently holds 505,449 shares of AstraZeneca PLC (AZN) worth $92.93 M, representing 1.28% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Sarah Ketterer has maintained a strategic position in AZN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 170,715 shares. Largest reduction occurred in Q2 2022, reducing 37,130 shares.
Analysis based on 13F filings available since 2013 Q2
Sarah Ketterer's AstraZeneca PLC (AZN) Holding Value Over Time
Track share changes against reported price movement
Quarterly AstraZeneca PLC (AZN) Trades by Sarah Ketterer
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -28,237 | Reduce 5.29% | 505,449 | $183.86 |
| Q3 2025 | +56,962 | Add 11.95% | 533,686 | $153.44 |
| Q2 2025 | +47,780 | Add 11.14% | 476,724 | $139.76 |
| Q1 2025 | +13,009 | Add 3.13% | 428,944 | $147.00 |
| Q4 2024 | +170,715 | Add 69.62% | 415,935 | $131.04 |
| Q3 2024 | +19,926 | Add 8.84% | 245,220 | $155.82 |
| Q2 2024 | -22,944 | Reduce 9.24% | 225,294 | $155.98 |
| Q1 2024 | +17,877 | Add 7.76% | 248,238 | $135.50 |
| Q4 2023 | +52,751 | Add 29.70% | 230,361 | $134.70 |
| Q3 2023 | +45,437 | Add 34.38% | 177,610 | $135.44 |
| Q2 2023 | -29,679 | Reduce 18.34% | 132,173 | $143.14 |
| Q1 2023 | +17,542 | Add 12.16% | 161,852 | $138.82 |
| Q4 2022 | -7,996 | Reduce 5.25% | 144,310 | $135.60 |
| Q3 2022 | -14,642 | Reduce 8.77% | 152,307 | $109.68 |
| Q2 2022 | -37,130 | Reduce 18.19% | 166,948 | $132.14 |
| Q1 2022 | +38,842 | Add 23.51% | 204,078 | $132.68 |
| Q4 2021 | -8,270 | Reduce 4.77% | 165,236 | $116.50 |
| Q3 2021 | +88,614 | Add 104.38% | 173,506 | $120.12 |
| Q2 2021 | +84,892 | New Buy | 84,892 | $119.80 |
Sarah Ketterer's AstraZeneca PLC Investment FAQs
Sarah Ketterer first purchased AstraZeneca PLC (AZN) in Q2 2021, acquiring 84,892 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer has held AstraZeneca PLC (AZN) for 19 quarters since Q2 2021.
Sarah Ketterer's largest addition to AstraZeneca PLC (AZN) was in Q4 2024, adding 415,935 shares worth $54.5 M.
According to the latest 13F filing for Q4 2025, Sarah Ketterer's firm, Causeway Capital Management LLC, owns 505,449 shares of AstraZeneca PLC (AZN), valued at approximately $92.93 M.
As of the Q4 2025 filing, AstraZeneca PLC (AZN) represents approximately 1.28% of Sarah Ketterer's publicly disclosed stock portfolio, making it one of their key holdings.
Sarah Ketterer's peak holding in AstraZeneca PLC (AZN) was 533,686 shares, as reported at the end of Q3 2025.